




कलावती सरन बाल चिकित्सालय
KALAWATI SARAN CHILDREN'S HOSPITAL
 बंगला साहिब मार्ग, नई दिल्ली-110001, Bangla Sahib Marg, New Delhi-110001

क्लीनिकल हिमेटोलॉजी लैब
CLINICAL HAEMATOLOGY LAB

नाम /Name	Ayan	आयु /Age	57	लिंग /Sex	Male
C.R. No.	31584	Consultant	Dr. V. Singh		
Ward/OPD	02 Day care.		Unit/Bed No.		
Date/Time	16/12/2024				
Nature of Anticoagulant	EDTA/Citrate/Heparin/Nil				
Diagnosis/History	CBC		 Signature of the Doctor		
Today's Lab. Ref. No.			Time of Receipt		

INCOMPLETE FORM IS NOT ACCEPTABLE

RET	[%]	[10 ⁶ /uL]		
IRF	[%]			
LFR	[%]			
MFR	[%]			
HFR	[%]			
RET-He	[pg]			
IPF	[%]			
WBC-BF	[10 ³ /uL]		RBC	PLT
RBC-BF	[10 ⁶ /uL]			
MN	[10 ³ /uL]	[%]		
PMN	[10 ³ /uL]	[%]		
TC-BF#	[10 ³ /uL]			
WBC IP Message		RBC IP Message	PLT IP Message	
Neutropenia		Anemia	Thrombocytopenia	
Lymphocytosis			PLT Clumps?	
Leukocytopenia				
Atypical Lympho?				

Duplicate Report

Sample No 1/643
Patient ID
Name
Sample Comment

08

Ward

Ajean
Tyim
18637


Rack

Position 3 2024/07/06 10:15:50 WB
Doctor
Sex 6/7/2024
Nickname XN-1500-1-R


Positive

Diff. Morph. Count

WBC	0.83	10 ³ /uL	
RBC	3.03	10 ⁶ /uL	
HGB	7.5	g/dL	
HCT	24.1	%	
MCV	79.5	fL	
MCH	24.8	pg	
MCHC	31.1	g/dL	
PLT	10	10 ³ /uL	
RDW-SD	----	fL	
RDW-CV	----	%	
PDW	----	fL	
MPV	----	fL	
P-LCR	----	%	
PCT	----	%	
NRBC	0.01	10 ³ /uL	1.2 %
NEUT	0.54	10 ³ /uL	65.1 %
LYMPH	0.25	10 ³ /uL	30.1 %
MONO	0.04	10 ³ /uL	4.8 %
EO	0.00	10 ³ /uL	0.0 %
BASO	0.00	10 ³ /uL	0.0 %
IG	0.00	10 ³ /uL	0.0 %
RET	0.92	%	0.0279 10 ⁶ /uL
IRF	15.7	%	
LFR	84.3	%	
MFR	11.3	%	
HFR	4.4	%	
RET-He	30.6	pg	
IPF		%	



DLG - N L E M
(200 cells) 144 50 00 06
RBC - NLC NLC with few
w/ hlc macrocytes and
occ. polychromatophil
grad. Adv. clinical
RET PLT-F
markedly



WBC-BF	10 ³ /uL	
RBC-BF	10 ⁶ /uL	
MN	10 ³ /uL	%
PMN	10 ³ /uL	%
TC-BF#	10 ³ /uL	



WBC IP Message
Neutropenia
Lymphopenia
Leukocytopenia

RBC IP Message
RBC Abn Distribution
Dimorphic Population
Anemia

PLT IP Message
PLT Abn Distribution
Thrombocytopenia

Sample No 20007 VICKY U2
 Patient ID
 Name
 Sample Comment

Ward


Rack

Position Doctor

Birth Nickname

WNR

WDF



Positive

Diff. Morph. Count

WBC	2.08	[10 ³ /uL]
RBC	2.39	[10 ⁶ /uL]
HGB	6.6	[g/dL]
HCT	22.0	[%]
MCV	92.1	[fL]
MCH	27.6	[pg]
MCHC	30.0	[g/dL]
PLT	49	[10 ³ /uL]
RDW-SD	43.7	[fL]
RDW-CV	13.5	[%]
PDW	12.9	[fL]
MPV	11.7	[fL]
P-LCR	36.3	[%]
PCT	0.06	[%]
NRBC	0.02	[10 ³ /uL]
NEUT	0.63	[10 ³ /uL]
LYMPH	0.65	[10 ³ /uL]
MONO	0.77	[10 ³ /uL]
EO	0.03	[10 ³ /uL]
BASO	0.00	[10 ³ /uL]
IG	0.06	[10 ³ /uL]
RET		[%]
IMF		[%]
IFR		[%]
HFR		[%]
RET-He		[pg]
IPF		[%]
WBC-BF		[10 ³ /uL]
RBC-BF		[10 ⁶ /uL]
MN		[10 ³ /uL]
PMN		[10 ³ /uL]
TC-BF#		[10 ³ /uL]

1.0	[10 ³ /uL]
30.3	[%]
31.3	[%]
37.0	[%]
1.4	[10 ³ /uL]
0.0	[10 ³ /uL]
2.9	[10 ³ /uL]

RET



PLT-F



RBC



PLT



WBC IP Message
 Neutropenia
 Lymphopenia
 Monocytosis
 Leukocytopenia
 Blasts/Abn Lympho?
 Atypical Lympho?

RBC IP Message
 Anemia

PLT IP Message
 Thrombocytopenia

Sample No: 11589 AY20-020
 Patient ID:
 Name:
 Sample Comment:

Ward: _____
 Rack: _____

Position: 12/12/2014 11:22:09 AM
 Doctor:
 Birth:
 Nickname: Zh 800-1-A

Positive
 Morph. Count

WBC	2.89	$10^3/\mu\text{L}$
RBC	1.53	$10^6/\mu\text{L}$
HGB	4.6	g/dL
HCT	14.2	%
MCV	92.8	fL
MCH	30.1	pg
MCHC	32.4	g/dL
PLT BF	21	$10^3/\mu\text{L}$
RDW-SO	52.4	fL
RDW-CV	15.7	%
PDW	----	fL
MPV	----	fL
P-LCR	----	%
PCT	----	%
NRBC	0.01	$10^3/\mu\text{L}$
NEUT	1.04 *	$10^3/\mu\text{L}$
LYMPH	0.97 *	$10^3/\mu\text{L}$
MONO	0.07 *	$10^3/\mu\text{L}$
EO	0.01	$10^3/\mu\text{L}$
BASO	0.00	$10^3/\mu\text{L}$
IG	0.01 *	$10^3/\mu\text{L}$
RET	0.76	%
IRF	17.1	%
LFR	82.9	%
MFR	12.4	%
HFR	4.7	%
RET-He	27.8	pg
IPF	9.5	%

0.5	%
49.8 *	%
46.4 *	%
3.3 *	%
0.5	%
0.5 *	%
0.0116	$10^6/\mu\text{L}$

WDF



WNR



RET



PLT-F



RBC



PLT



WBC-BF	$10^3/\mu\text{L}$
RBC-BF	$10^6/\mu\text{L}$
MN	$10^3/\mu\text{L}$
PMN	$10^3/\mu\text{L}$
TC-BFR	$10^3/\mu\text{L}$

%
 %

WBC IP Message
 Leukocytopenia
 Atypical Lympho?

RBC IP Message
 Anemia

PLT IP Message
 PLT Abn Distribution
 Thrombocytopenia

High Risk, Interim Maintenance Phase

Phase	1	2	3	4	5	6	7	8	9	10	11	12
Phase 1												
Phase 2												
Phase 3												
Phase 4												
Phase 5												
Phase 6												
Phase 7												
Phase 8												
Phase 9												
Phase 10												
Phase 11												
Phase 12												

1. The purpose of this phase is to ensure that all critical components are inspected and maintained at the highest level of safety. This includes a thorough review of all safety-critical systems and a detailed inspection of all critical components.

2. The primary objective of this phase is to identify and address any potential safety hazards or deficiencies that could compromise the integrity of the system. This includes a thorough review of all safety-critical systems and a detailed inspection of all critical components.

3. The secondary objective of this phase is to ensure that all safety-critical systems are properly configured and tested. This includes a thorough review of all safety-critical systems and a detailed inspection of all critical components.

4. The final objective of this phase is to ensure that all safety-critical systems are properly documented and maintained. This includes a thorough review of all safety-critical systems and a detailed inspection of all critical components.

7. GMP

M	S	W	T	F	S	S
1/2	1/2	1/2	1/2	1/2	-	-





Mob. : 9821233869

JEEVAN CARE FOUNDATION

Address:- 697, Village Madanpur Khadar, New Delhi 110076

Mail- Jeevancarefoundation@gmail.com

Reg No. 92

Ref. No.

Date 27/12/24

सेवा

संस्थापक अध्यक्ष

जीवन केयर माउडेशन

मिथव्य

मैं गुरु शर्मा अपने लक्ष्य आधान के लिए
 आप सभी से विनती करती हूँ
 मेरा लक्ष्य आधान ब्लड कैंसर जैसी
 असह्य है क्यूंकि रहा है, हमारे पुरा
 परिवार जीवन भर आप पर अमारी रहेगा
 मेरे लक्ष्य को मर्या जीवन दान कर
 कृपा कर उत्तमी मदद करे। कृपा
 करने साहायत करे। कृपा
 कृपा होगी।

